Parmax Pharma Ltd.
Fundamentals
- Market cap
- ₹16.74 cr
- ROE
- 105.30%
- Debt / equity
- -4.07
- 52-week range
- 22.60 — 45.87
The timeline — 2 notes on Parmax Pharma Ltd.
June 2026
- 03 Jun 26 · 9:18 PM IST Lead Lead · Micro cap
Parmax Pharma turns to a preferential issue after a 57% revenue crash.
A nano-cap with a ₹14 crore market cap, ₹4.16 crore in annual losses, and auditors flagging the Managing Director's fund use is seeking fresh equity.
- 03 Jun 26 · 6:47 PM IST Brief Brief · Earnings · Micro cap
Parmax Pharma revenue halved, auditors flag MD's use of company funds
FY26 revenue fell 57% to ₹12.11 crore as auditors qualified the accounts over unauthorized mutual fund purchases in the managing director's name.